GLP-1 receptor agonist medications (including semaglutide, dulaglutide, liraglutide, exenatide, and lixisenatide) are typically considered for type 2 diabetes when: Triple therapy with other diabetes medications is not effective, not tolerated, or contraindicated The person has a BMI 35 kg/m (adjusted by 2.5 kg/m for people from South Asian, Chinese, other Asian, Black African, or African-Caribbean backgrounds) and specific weight-related psychological or medical problems A lower BMI threshold may be appropriate if weight loss would benefit other obesity-related comorbidities Insulin would not be appropriate or acceptable to the person Treatment is usually continued only if there is a beneficial metabolic response (reduction in HbA1c and weight) after 6 months
Akhatova A, Jones C, Coward K, Yeste M
If you miss a dose, follow product-specific instructions: For Ozempic, if more than 5 days have passed, skip that dose and take the next dose on the regularly scheduled day
doi: 10.3389/fendo.2021.735019 79 LazzaroniEBen NasrMLoretelliCPastoreIPlebaniLLunatiMEet al
However, this pathway carries both opportunities and substantial risks that must be carefully navigated
